Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Bladder Cancer

  Free Subscription


06.10.2025

2 Actas Urol Esp (Engl Ed)
1 Am J Case Rep
1 Ann Surg Oncol
1 Anticancer Res
1 Arch Ital Urol Androl
1 Biochim Biophys Acta Rev Cancer
1 bioRxiv
1 Biosens Bioelectron
1 BJU Int
2 BJUI Compass
2 BMC Cancer
1 BMC Immunol
1 BMC Microbiol
1 BMC Urol
1 Cancer Drug Resist
1 Cancer Med
1 Cancers (Basel)
1 Chem Biol Interact
1 Comb Chem High Throughput Screen
1 Commun Biol
2 Cureus
1 Curr Treat Options Oncol
1 Dermatol Online J
3 Discov Oncol
1 Drug Dev Res
1 Eur J Cancer
2 Eur J Surg Oncol
7 Eur Urol
1 Expert Opin Drug Saf
1 Expert Rev Mol Diagn
2 Front Immunol
3 Front Oncol
1 Hinyokika Kiyo
1 Int J Clin Oncol
1 Int Urol Nephrol
1 Ir J Med Sci
1 J Appl Biomed
1 J Chemother
1 J Health Popul Nutr
1 J Immunother Cancer
1 J Mol Diagn
1 J Pathol
1 J Transl Med
1 Korean J Radiol
1 Med Sci (Basel)
2 Medicine (Baltimore)
1 Mol Carcinog
1 Niger J Clin Pract
1 NPJ Precis Oncol
1 Oncology
2 Pharmaceuticals (Basel)
3 Sci Rep
1 Semin Nucl Med
1 Sensors (Basel)
1 Surg Neurol Int
3 Urol Int
4 Urol Oncol
1 Virchows Arch
1 World J Surg Oncol
2 World J Urol


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Actas Urol Esp (Engl Ed)

  1. JUSTE-ALVAREZ S, Garcia-Rayo Encina C, Gomez Del Canizo C, Hernandez-Arroyo M, et al
    Comparison of prognosis between primary and progressive muscle-invasive bladder carcinoma: A prospective analysis of long-term outcomes after radical cystectomy.
    Actas Urol Esp (Engl Ed). 2025;49:501815.
    PubMed         Abstract available

  2. CAYUELA L, Achaval V, Cabrera Fernandez S, Ortega Calvo M, et al
    Sex-specific bladder cancer incidence trends and generational effects in Spain.
    Actas Urol Esp (Engl Ed). 2025 Sep 29:501863. doi: 10.1016/j.acuroe.2025.501863.
    PubMed         Abstract available


    Am J Case Rep

  3. OKE I, Lenert A, Swick BL, Lenert P, et al
    Eosinophilic Fasciitis in a 78-Year-Old Man Following Pembrolizumab Treatment for Bladder Cancer.
    Am J Case Rep. 2025;26:e948323.
    PubMed         Abstract available


    Ann Surg Oncol

  4. LAI S, Wu P, Liu J, Song Y, et al
    ASO Author Reflections: Navigating the Dual Threat-Bladder Cancer's Impact on Upper Tract Urothelial Carcinoma Outcomes.
    Ann Surg Oncol. 2025 Sep 26. doi: 10.1245/s10434-025-18004.
    PubMed        


    Anticancer Res

  5. NISHIO K, Hirosuna K, Uchimoto T, Niigawa H, et al
    Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial Carcinoma.
    Anticancer Res. 2025;45:4575-4583.
    PubMed         Abstract available


    Arch Ital Urol Androl

  6. PUBLISHER T
    Correction. Current status of management and outcomes of muscle-invasive bladder cancer in Yemen: a retrospective observational study.
    Arch Ital Urol Androl. 2025;97:14449.
    PubMed         Abstract available


    Biochim Biophys Acta Rev Cancer

  7. KANG H, Liu X, Ge D, Zeng Y, et al
    Revolutionizing bladder cancer research: Harnessing 3D organoid technology to decode tumor heterogeneity and propel personalized therapeutics.
    Biochim Biophys Acta Rev Cancer. 2025;1880:189454.
    PubMed         Abstract available


    bioRxiv

  8. CARVALHO FL, Lee J, Kalavros N, Zhou Y, et al
    Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancer.
    bioRxiv [Preprint]. 2025 Sep 15:2025.09.08.674862.
    PubMed         Abstract available


    Biosens Bioelectron

  9. CHEN W, Song L, Luo J, Tang J, et al
    Uranalysis-tailored fluorogenic strategy for monitoring bladder cancer biomarker hyaluronidase-1 by harnessing hydrogen-bonding-induced emission.
    Biosens Bioelectron. 2025;291:118060.
    PubMed         Abstract available


    BJU Int

  10. RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al
    External validation of the Uromonitor(R)-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management.
    BJU Int. 2025 Oct 1. doi: 10.1111/bju.70010.
    PubMed         Abstract available


    BJUI Compass

  11. MIYAKE M, Tokumaru J, Oi H, Kitagawa H, et al
    Real-world use of maintenance bacillus Calmette-Guerin therapy in patients with non-muscle-invasive bladder cancer in Japan: ASUKA study.
    BJUI Compass. 2025;6:e70091.
    PubMed         Abstract available

  12. HURLE R, Capalbo A, Lughezzani G, Buffi NM, et al
    Germline homologous recombination repair (gHRR) variants in bladder cancer: Preliminary evidence and clinical implications.
    BJUI Compass. 2025;6:e70077.
    PubMed         Abstract available


    BMC Cancer

  13. LIU S, Lei K, Li G, Zheng P, et al
    The integration of transcriptomics and metabolomics elucidates the antitumor mechanisms of mycophenolic acid in bladder cancer cells.
    BMC Cancer. 2025;25:1463.
    PubMed         Abstract available

  14. CHEN B, Zhou Y, Li Z, Chen J, et al
    A study on predicting recurrence of non-muscle-invasive bladder cancer within 2 years using mp-MRI radiomics.
    BMC Cancer. 2025;25:1497.
    PubMed        


    BMC Immunol

  15. NAITO H, Taoka R, Zhang X, Hossain A, et al
    Enfortumab vedotin promotes PD-L1 expression in urothelial carcinoma via NF-kappaB and STAT3 pathways highlighting mechanisms of immune evasion and potential for combination therapy.
    BMC Immunol. 2025;26:70.
    PubMed         Abstract available


    BMC Microbiol

  16. KANG C, Lee J, Baek MG, Kim NE, et al
    Urinary microbiome in non-muscle invasive bladder cancer: impact of sample types and sex differences.
    BMC Microbiol. 2025;25:623.
    PubMed         Abstract available


    BMC Urol

  17. LI X, Wang J, Wang K, Tan S, et al
    Analysis of risk factors for postoperative bladder cancer in patients with upper tract urothelial carcinoma and construction of nomogram prediction model.
    BMC Urol. 2025;25:247.
    PubMed         Abstract available


    Cancer Drug Resist

  18. CUPRYCH-BELTER M, Lupicka-Slowik A, Anisiewicz A, Michaelis M, et al
    Distinct adaptive strategies to cisplatin, vinblastine and gemcitabine in a panel of chemoresistant bladder cancer cell lines.
    Cancer Drug Resist. 2025;8:49.
    PubMed         Abstract available


    Cancer Med

  19. NIZAM A, Nguyen CB, Li J, Zabor EC, et al
    Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.
    Cancer Med. 2025;14:e71284.
    PubMed         Abstract available


    Cancers (Basel)

  20. CUSUMANO C, Squillante F, Roma M, Miano R, et al
    Bladder Cancer: Uncovering the Predictive Role of NOTCH as an Emerging Candidate Biomarker for Therapeutic Strategies.
    Cancers (Basel). 2025;17:3078.
    PubMed         Abstract available


    Chem Biol Interact

  21. LIN L, Kong L, Dong X, Ma S, et al
    Sevoflurane suppresses growth and metastasis of bladder cancer cells via inducing ferroptosis and antitumor microenvironment through Akt/mTOR/SREBP1 signaling.
    Chem Biol Interact. 2025 Oct 1:111766. doi: 10.1016/j.cbi.2025.111766.
    PubMed         Abstract available


    Comb Chem High Throughput Screen

  22. LI H, Liang Y, Tang J, Luo H, et al
    YBX1 Enhances the Stability of TM4SF1 in an m5C-Dependent Manner to Promote Bladder Cancer Proliferation and Glycolysis.
    Comb Chem High Throughput Screen. 2025.
    PubMed         Abstract available


    Commun Biol

  23. HE J, Dong C, Song X, Bao X, et al
    MFSD12, transcriptionally regulated by PLAGL2, promotes bladder cancer progression.
    Commun Biol. 2025;8:1402.
    PubMed         Abstract available


    Cureus

  24. SAITO Y, Adomi S, Sakai K, Antonio De Velasco M, et al
    Evaluation of Telomerase Reverse Transcriptase (TERT) Promoter Mutations in Photodynamic Diagnosis With 5-Aminolevulinic Acid False-Positive Sites in Non-muscle-Invasive Bladder Cancer.
    Cureus. 2025;17:e90860.
    PubMed         Abstract available

  25. GORSKI J, Gajewski W, Ziembicki H, Pierudzka W, et al
    Nanoparticles as Drug Delivery Systems in Intravesical Therapy for Non-muscle Invasive Bladder Cancer: A Narrative Review.
    Cureus. 2025;17:e91103.
    PubMed         Abstract available


    Curr Treat Options Oncol

  26. MENG L, Khorasanchi A, Jain R
    Advancing Bladder Cancer Management: The Role of Neoadjuvant and Adjuvant Therapies and Biomarkers in Muscle Invasive Bladder Cancer.
    Curr Treat Options Oncol. 2025 Sep 26. doi: 10.1007/s11864-025-01355.
    PubMed         Abstract available


    Dermatol Online J

  27. WANG R, Fernandez K, Zelman B, Speiser J, et al
    Enfortumab vedotin-induced bullous dermatitis.
    Dermatol Online J. 2025;31.
    PubMed         Abstract available


    Discov Oncol

  28. LIU J, Zhang Z, Huang B, Fang Y, et al
    A GRK5 centered prognostic framework for bladder cancer based on palmitoylation and epigenetic regulation.
    Discov Oncol. 2025;16:1735.
    PubMed         Abstract available

  29. MA X, Quan C
    Identification of KIF14 as a ferroptosis biomarker for predicting the prognosis and immunotherapy efficacy of bladder cancer.
    Discov Oncol. 2025;16:1786.
    PubMed         Abstract available

  30. WANG Y, Zhou T, Hu C, Chen H, et al
    Prognostic analysis and immunotherapy prediction based on key receptor-ligand pairs of bladder cancer.
    Discov Oncol. 2025;16:1784.
    PubMed         Abstract available


    Drug Dev Res

  31. SILVA LWPE, Almeida TC, Teixeira MSDS, Cerrutti CMV, et al
    Antiproliferative Effects of the Triterpene Ursolic Acid Natural Product in Bladder and Ovarian Tumor Cell Lines.
    Drug Dev Res. 2025;86:e70172.
    PubMed         Abstract available


    Eur J Cancer

  32. STOCKEM CF, van Dorp J, van Dijk N, Vis DJ, et al
    Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trial.
    Eur J Cancer. 2025;229:115731.
    PubMed         Abstract available


    Eur J Surg Oncol

  33. RAUTIOLA J, Bjorklund J, Zelic R, Pellegrino F, et al
    Pelvic lymph-node dissections in bladder and prostate cancer surgery and the risk of postoperative venous thromboembolism.
    Eur J Surg Oncol. 2025;51:110326.
    PubMed         Abstract available

  34. NICOLAZZINI M, Longoni M, Falkenbach F, Marmiroli A, et al
    Robot-assisted vs. open radical cystectomy: octogenarians vs. non octogenarians.
    Eur J Surg Oncol. 2025;51:110345.
    PubMed         Abstract available


    Eur Urol

  35. GALSKY MD, van der Heijden MS, Powles T, Claps M, et al
    Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial.
    Eur Urol. 2025;88:325-330.
    PubMed         Abstract available

  36. BELLMUNT J, Powles T, Park SH, Voog E, et al
    Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease.
    Eur Urol. 2025;88:331-338.
    PubMed         Abstract available

  37. LI X, Wang X, Zhang G
    Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur
    Eur Urol. 2025 Sep 24:S0302-2838(25)04654-8. doi: 10.1016/j.eururo.2025.
    PubMed        

  38. PHARO H, Vedeld HM, Wahlqvist R, Lind GE, et al
    Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur
    Eur Urol. 2025 Sep 24:S0302-2838(25)04646-9. doi: 10.1016/j.eururo.2025.
    PubMed        

  39. SHI Z, Yang S, Yang Y
    Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur
    Eur Urol. 2025 Sep 27:S0302-2838(25)04682-2. doi: 10.1016/j.eururo.2025.
    PubMed        

  40. ROVIELLO G, Antonuzzo L
    Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur
    Eur Urol. 2025 Sep 27:S0302-2838(25)04695-0. doi: 10.1016/j.eururo.2025.
    PubMed        

  41. DREYER T, Jensen JB
    Reply to Heidi Pharo, Hege Marie Vedeld, Rolf Wahlqvist, and Guro E. Lind's Letter to the Editor re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade
    Eur Urol. 2025 Sep 25:S0302-2838(25)04642-1. doi: 10.1016/j.eururo.2025.09.4129.
    PubMed        


    Expert Opin Drug Saf

  42. WANG B, Bao EH, Jiang BL, Yang L, et al
    Signal mining and gender differences analysis of adverse events in NMIBC treatment with gemcitabine and BCG bladder instillation based on the FAERS database.
    Expert Opin Drug Saf. 2025;24:1241-1248.
    PubMed         Abstract available


    Expert Rev Mol Diagn

  43. AMIN A, Khalatbari F, Cheng L
    Genetic profiling of upper tract urothelial carcinoma: A necessity for precision medicine.
    Expert Rev Mol Diagn. 2025;25:695-708.
    PubMed         Abstract available


    Front Immunol

  44. WANG L, Chang Z, Chen SY, Yang JW, et al
    Multi-omics dissection of fatty acid metabolism heterogeneity identifies PRDX1 as a prognostic marker in bladder cancer.
    Front Immunol. 2025;16:1669822.
    PubMed         Abstract available

  45. ZHOU Z, Chen Y, Wang Z, Yang S, et al
    Characterization of cancer-related fibroblasts in bladder cancer and construction of CAFs-based bladder cancer classification: insights from single-cell and multi-omics analysis.
    Front Immunol. 2025;16:1580986.
    PubMed         Abstract available


    Front Oncol

  46. CHEN X, Jiang K, Chen K, An Y, et al
    HOXB7 drives bladder cancer progression via H-Ras/ERK signaling: a potential therapeutic target and prognostic biomarker.
    Front Oncol. 2025;15:1645803.
    PubMed         Abstract available

  47. TANG Q, Li Y, Liu K, Huang G, et al
    Development and validation of a risk prediction model for distant metastasis in muscle-invasive bladder cancer: a retrospective study integrating SEER data with external validation cohort and biomarker analysis.
    Front Oncol. 2025;15:1607173.
    PubMed         Abstract available

  48. WANG L, Wang Y, Wang Y, Wang Z, et al
    Prognostic value and molecular mechanism of photodynamic therapy and apoptosis related gene FGFR1 in bladder cancer.
    Front Oncol. 2025;15:1578695.
    PubMed         Abstract available


    Hinyokika Kiyo

  49. TSUKADA H, Hayakawa N, Sasaki M, Matsubara K, et al
    [Vaginal and Vulval Secondary Extramammary Paget's Disease Associated with Urothelial Carcinoma in Situ : A Case Report].
    Hinyokika Kiyo. 2025;71:301-305.
    PubMed         Abstract available


    Int J Clin Oncol

  50. QAISAR R, Hussain S, Ahmad F, Karim A, et al
    Plasma CAF22 and NfL reflect neuromuscular decline during cisplatin-based chemotherapy and radical cystectomy in muscle-invasive bladder cancer.
    Int J Clin Oncol. 2025 Sep 27. doi: 10.1007/s10147-025-02890.
    PubMed         Abstract available


    Int Urol Nephrol

  51. YENTUR S, Canitez IO, Dusunus YE, Sahin S, et al
    Simultaneous transurethral resection of the prostate and bladder tumor: a safety and efficacy analysis.
    Int Urol Nephrol. 2025;57:3219-3226.
    PubMed         Abstract available


    Ir J Med Sci

  52. SUNGUR U, Kerim Ozfiliz N, Eksi M, Kargi T, et al
    Assessing the use of modified 5-item frailty index as a prognostic marker of long-term survival and perioperative outcomes after radical cystectomy for bladder cancer.
    Ir J Med Sci. 2025 Oct 3. doi: 10.1007/s11845-025-04108.
    PubMed         Abstract available


    J Appl Biomed

  53. ELSALEM L, Aleikish AA, Al-Azzam N, Alfaqih MA, et al
    Serum xanthine oxidoreductase and oxidative stress are associated with bladder cancer: a case-control study from Jordan.
    J Appl Biomed. 2025;23:107-116.
    PubMed         Abstract available


    J Chemother

  54. SU M, Chen W, Luo J, Li X, et al
    E2F1-induced transcriptional activation of MAL2 inhibits sunitinib sensitivity and promotes the malignant progression of bladder cancer.
    J Chemother. 2025 Sep 26:1-12. doi: 10.1080/1120009X.2025.2561275.
    PubMed         Abstract available


    J Health Popul Nutr

  55. HOSSEINI AS, Jalali SM, Shateri Z, Shoja M, et al
    The association between digestion-resistant and bioactive peptide content of dairy products and bladder cancer: a case-control study.
    J Health Popul Nutr. 2025;44:336.
    PubMed         Abstract available


    J Immunother Cancer

  56. SCHAFER JM, Song NJ, Xiao T, Gauntner TD, et al
    T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancer.
    J Immunother Cancer. 2025;13:e012050.
    PubMed         Abstract available


    J Mol Diagn

  57. HERRANZ R, Oto J, Plana E, Perez-Ardavin J, et al
    Analysis of the Fragmentation and Integrity of Urine Cell-Free DNA as Diagnostic and Staging Biomarker for Bladder Cancer.
    J Mol Diagn. 2025 Sep 26:S1525-1578(25)00222.
    PubMed         Abstract available


    J Pathol

  58. LEE S, Jung SY, Kus P, Bondaruk J, et al
    Dysregulated mitochondrial energy metabolism drives the progression of mucosal field effects to invasive bladder cancer.
    J Pathol. 2025 Sep 25. doi: 10.1002/path.6474.
    PubMed         Abstract available


    J Transl Med

  59. ZHANG H, Huang W, Cai Z, Mou S, et al
    CCDC137 knockdown suppresses bladder cancer progression by downregulating SCD.
    J Transl Med. 2025;23:1013.
    PubMed         Abstract available


    Korean J Radiol

  60. EID S, Al-Yousef AS, Kim KW, Yoon S, et al
    State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder Cancer.
    Korean J Radiol. 2025;26:959-972.
    PubMed         Abstract available


    Med Sci (Basel)

  61. KRAEVSKA E, Popovska S
    Immunohistochemistry-Based Molecular Profiling of Muscle-Invasive Bladder Cancer: Analysis of 100 Consecutive Cases with Morphological Correlation.
    Med Sci (Basel). 2025;13:202.
    PubMed         Abstract available


    Medicine (Baltimore)

  62. HU A, Hu C, Lin Y, Zhu X, et al
    Causal relationship between immune cells and bladder cancer: A bidirectional Mendelian randomization study.
    Medicine (Baltimore). 2025;104:e44268.
    PubMed         Abstract available

  63. CATAL MN, Akarken I, Dere Y, Deliktas H, et al
    Prognostic difference of molecular subtypes in non-muscle invasive bladder cancer.
    Medicine (Baltimore). 2025;104:e44808.
    PubMed         Abstract available


    Mol Carcinog

  64. ZHANG L, Zhou L, Xu W, Wu P, et al
    RNA m(5)C Modifications in the Development and Prognosis of Muscle-Invasive Bladder Cancer.
    Mol Carcinog. 2025 Sep 25. doi: 10.1002/mc.70042.
    PubMed         Abstract available


    Niger J Clin Pract

  65. AKYUZ M, Kayar R, Ozsoy E, Artuk I, et al
    Impact of the CALLY Index in Predicting Overall Survival and Disease-Free Survival in Patients Undergoing Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    Niger J Clin Pract. 2025;28:1090-1096.
    PubMed         Abstract available


    NPJ Precis Oncol

  66. JURIC I, Fink EE, Qiu H, Desprez PE, et al
    Single-cell RNA-sequencing of BCG naive and recurrent non-muscle invasive bladder cancer reveals a CD6/ALCAM-mediated immune-suppressive pathway.
    NPJ Precis Oncol. 2025;9:318.
    PubMed         Abstract available


    Oncology

  67. NEGISHI T, Kobayashi H, Furubayashi N, Morihara K, et al
    Health-Related Quality of Life in a Real-World Cohort of Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
    Oncology. 2025;103:921-929.
    PubMed         Abstract available


    Pharmaceuticals (Basel)

  68. PEREIRA M, Vale N
    Exploring Potential for Repurposing Antiretroviral Drugs Etravirine and Efavirenz in Prostate and Bladder Cancer.
    Pharmaceuticals (Basel). 2025;18:1404.
    PubMed         Abstract available

  69. SAKAI AH, Pereira ER, Santos AGPD, Quadreli DH, et al
    miR-25-3p Modulates Tumor Aggressiveness and Ferroptosis Escape in T24 Bladder Cancer Cells In Vitro.
    Pharmaceuticals (Basel). 2025;18:1382.
    PubMed         Abstract available


    Sci Rep

  70. HUANG X, Meng Y, Song J, Zhu Y, et al
    Identification of biomarkers associated with mitophagy in bladder cancer.
    Sci Rep. 2025;15:33272.
    PubMed         Abstract available

  71. SILVA IM, Vacario BGL, Maraslis FT, Koike A, et al
    GLRX2 polymorphism and oxidative stress levels impact urothelial bladder cancer outcomes.
    Sci Rep. 2025;15:34041.
    PubMed         Abstract available

  72. AMPARO TR, da Anunciacao KF, Almeida TC, de Oliveira AB, et al
    Lapachol interferes with the cell cycle and inhibits proliferation and migration of bladder tumor cells with effects on ncRNA expression.
    Sci Rep. 2025;15:33829.
    PubMed         Abstract available


    Semin Nucl Med

  73. KABUNDA J, Ndlovu H, Singh K, Sibiya S, et al
    Nectin-4, Bladder Cancer, and Nuclear Medicine: A Theranostic Frontier.
    Semin Nucl Med. 2025 Sep 26:S0001-2998(25)00118.
    PubMed         Abstract available


    Sensors (Basel)

  74. REMMELINK MJ, Bloemen PR, van der Voorn P, Attendu X, et al
    Ex Vivo Optical Coherence Tomography Analysis of Resected Human Bladder with a Forward-Looking Microelectromechanical Systems Mirror-Based Catheter.
    Sensors (Basel). 2025;25:5794.
    PubMed         Abstract available


    Surg Neurol Int

  75. BAGHERZADEH S, Roohollahi F, Kopparapu S, Carballo Cuello CM, et al
    Posterior-only total en bloc spondylectomy of L4 for solitary bladder cancer metastasis - An illustrative case.
    Surg Neurol Int. 2025;16:360.
    PubMed         Abstract available


    Urol Int

  76. NAKANISHI Y, Nakanishi Y, Ogasawara RA, Imasato N, et al
    Separated Transfixing Uretero-Enteral Anastomosis Method in Robot-Assisted Radical Cystectomy with Ileal Conduit: Early Induction Experience.
    Urol Int. 2025;109:546-552.
    PubMed         Abstract available

  77. BAHLBURG H, Bahlburg H, Rausch P, Silberg M, et al
    Stage Migration in Urological Cancers in Germany during the COVID-19 Pandemic: Fact or Fiction?
    Urol Int. 2025;109:501-507.
    PubMed         Abstract available

  78. PATTOU M, Ochoa A, Goujon A, Verine J, et al
    Outpatient Transurethral Resections of Bladder Tumors: Insights from the Largest Cohort to Date.
    Urol Int. 2025;109:471-477.
    PubMed         Abstract available


    Urol Oncol

  79. GUAN B, Wang G, Zhang H, Xia M, et al
    Does ureteral stent drainage prior to radical nephroureterectomy increase the risk of intravesical tumor recurrence?
    Urol Oncol. 2025;43:662.
    PubMed         Abstract available

  80. CITGEZ S, Bulbul E, Ozden SB, Ilki FY, et al
    Benign ureteroenteric anastomotic stricture predictors in radical cystectomy patients: A critical analysis focusing on the nutritional risk index and postoperative urinary tract infection.
    Urol Oncol. 2025 Aug 12:S1078-1439(25)00271.
    PubMed         Abstract available

  81. OBAID K, Akpinar C, Karaburun MC, Ibis MA, et al
    A randomized prospective trial comparing Bacillus Calmette-Guerin (BCG) RIVM and Russian strains in non-muscle invasive bladder cancer: Efficacy and side effects.
    Urol Oncol. 2025 Sep 25:S1078-1439(25)00349.
    PubMed         Abstract available

  82. TITUS RS, Mundra V, Velasquez EL, Xu J, et al
    The association between prior pelvic radiotherapy for cancer and surgical outcomes in patients undergoing radical cystectomy for bladder cancer: An analysis of national surgical quality improvement program targeted cystectomy database.
    Urol Oncol. 2025 Sep 25:S1078-1439(25)00342.
    PubMed         Abstract available


    Virchows Arch

  83. ZHAO M, Zhang P, Xu J, Wang S, et al
    Small cell carcinoma with rhabdomyosarcomatous differentiation of the urinary bladder: an integrated clinicopathological and molecular characterization of five cases.
    Virchows Arch. 2025;487:523-533.
    PubMed         Abstract available


    World J Surg Oncol

  84. ZHU Z, Zhu Y, Ying W, Wu H, et al
    Comparison of the anti-reflux ileum valve-pouch orthotopic neobladder and the Studer technique after radical cystecomy: surgical and renal functional outcomes.
    World J Surg Oncol. 2025;23:359.
    PubMed         Abstract available


    World J Urol

  85. ESCOBAR D, Zahir M, Doshi C, Daneshmand S, et al
    Management of clinical stage T3/T4 bladder cancer: a review.
    World J Urol. 2025;43:583.
    PubMed         Abstract available

  86. AZHAR Z, Sadia Z
    Inlexzo (gemcitabine intravesical system): promising data but key questions remain.
    World J Urol. 2025;43:586.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.